NCT01604733已完成不适用
Centralized Pan-Middle East Survey on the Undertreatment of Hypercholesterolemia
适应症
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 发起方
- AstraZeneca
- 入组人数
- 1,000
- 主要终点
- The proportion of patients on lipid-lowering treatment reaching the LDL-C goals according to the NCEP ATP III/ updated 2004 NCEP ATP III , overall and by country
研究概览
简要总结
Study objective is to evaluate the level of control of hypercholesterolemia in Egypt in patients taking lipid lowering agents for at least 3 months ( with no drug change or dose amendment for a minimum of 6 weeks).
详细描述
Centralized Pan-Middle East Survey on the Undertreatment of Hypercholesterolemia
研究设计
- 研究类型
- Observational
- 时间视角
- Cross Sectional
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •18 years and above on current lipid lowering drug for at least 3 months with no dose change for a minimum of 6 weeks
- •Subject must provide informed consent and comply with the survey procedures
排除标准
- •Less than 18 years less than 3 months on antidyslipidemic agent Subjects who are unwilling or unable to provide informed consent
结局指标
主要结局
The proportion of patients on lipid-lowering treatment reaching the LDL-C goals according to the NCEP ATP III/ updated 2004 NCEP ATP III , overall and by country
时间窗: 24 weeks
次要结局
- The proportion of patients on lipid-lowering treatment reaching the LDL-C goals according to the NCEP ATP III/ updated 2004 NCEP ATP III , in the following sub-populations: - primary/secondary prevention patients and with metabolic syndromes(24 weeks)
- The proportion of patients on lipid-lowering treatment reaching the LDL-C goals according to the Third Joint European Task Force guideline, in the following sub-populations: - primary/secondary prevention patients and with metabolic syndromes(24 weeks)
- Determinants (e.g. patient and physician characteristics , country-specific guidelines or recommendations) for undertreatment of hypercholesterolemia(24 weeks)
- Physician characteristics associated with the allocation of treatment regimen.(24 weeks)
- The proportion of patients on lipid-lowering treatment reaching the non HDL-C goals according to the NCEP ATP III/ updated 2004 NCEP ATP III , in the sub-population patients with fasting triglycerides<200 mg/d(24 weeks)
研究者
相似试验
已完成
不适用
Centralized Pan-Middle East Survey on the Undertreatment of HypercholesterolemiaHypercholesterolemiaNCT01025388AstraZeneca4,053
已完成
不适用
Centralised Pan-Algerian Survey on the Undertreatment of HypercholesterolemiaHypertensionHypercholesterolemiaPeripheral Arterial DiseaseDiabetesCardiovascular DiseaseCoronary Heart DiseaseNCT01768403AstraZeneca1,236
已完成
不适用
Polish Survey on the Efficacy of the Hypercholesterolemia TreatmentHypercholesterolemiaNCT01243255AstraZeneca1,500
已完成
不适用
Centralized Pan-Middle East Survey on the Under-treatment of Hypercholesterolemia, Sub-study for the Gulf StatesHypercholesterolemiaNCT01031277AstraZeneca1,000
已完成
不适用
InPractice Survey on the Treatment of HypercholesterolemiaHypercholesterolemiaNCT00523796AstraZeneca2,500